Introduction: Radiation Therapy Oncology Group 97-14 concluded that a single fraction of radiation was as effective in relieving pain as multiple fractions in the treatment of patients with bone metastases. A statistically significant higher retreatment rate, however, was noted in patients undergoing a single fraction treatment. The purpose of the analysis was to determine whether multiple fraction treatment is cost-effective in treating patients with bone metastasis, by preventing further retreatment. Methods and Material: A Markov model was used to evaluate the costeffectiveness of 30 Gy in 10 fractions in comparison with 8 Gy in 1 fraction. Transition probabilities, cost, and utilities were obtained from the clinical trial. Costs and outcomes were not discounted because of the short time line for the study. Results: The expected mean cost and quality-adjusted survival in months for patients receiving 8 Gy in 1 fraction and 30 Gy in 10 fractions was $998 and 7.26 months and $2316 and 9.53 months, respectively. The incremental cost-effectiveness ratio was $6973/quality-adjusted life year. The results were sensitive to the utility of the posttreatment state for both single and multiple fraction treatments. Conclusion: Single fraction treatment was the less expensive treatment in the treatment of patients with bone metastasis treated on Radiation Therapy Oncology Group 97-14. FIGURE 2. This figure depicts the flow of patients in the model for multiple fractions. Patients start out in multiple radiation treatment (MRT) and move through the model, as determined by the transitions probabilities.
A single fraction of radiation is as effective as multiple fractions in the palliation of painful bone metastasis. [1] [2] [3] [4] [5] Retreatment rates, however, are higher in patients undergoing a single fraction radiation therapy but overall pain control is similar between groups. Radiation Therapy Oncology Group (RTOG) 97-14 evaluated the ability of a single fraction of radiation therapy to relieve painful bone metastases from breast and prostate cancer in comparison with that of multiple fractions. 6 Three-year updated results have confirmed the earlier report of similar overall pain relief between fractionation schedules but with higher retreatment rates in the 8 Gy fraction treatment (18%) in comparison with 9% for patients treated with 30 Gy. 7 Single fraction treatment is less expensive and time consuming for patients and families in comparison with multiple fraction treatment. But, would the higher retreatment rate experienced by patients counter the initial cost savings? Single fraction treatment resulted in comparable palliation and quality of life with lower medical and societal costs in comparison with multiple fraction treatment in a subset of 166 patients treated in the Dutch Bone Metastasis Study in The Netherlands. 8 This study randomized patients to either a single fraction of 8 Gy or 6 fractions of 4 Gy. 1 The decision for retreatment was at the discretion of the physician and was found to be higher in the single fraction arm of the Dutch Bone Metastasis Study. Reasons given for higher rates of retreatment in the single fraction arm included less concern over radiation tolerance of adjacent normal structures.
The specific aim of this study was to perform an economic analysis comparing 8 Gy in 1 fraction to 30 Gy in 10 fractions, using a Markov model, with data from RTOG 97-14. We hypothesize that, although initially more costly, multiple fraction radiation treatments will be cost-effective within the range of acceptability of $50,000/ quality-adjusted life year (QALY).
METHODS AND MATERIALS
A Markov model was developed and informed with data from RTOG 97-14. The health states and transition probabilities for this clinical scenario have been previously published. 9 The Markov model was created for patients to spend 1 month in each state before transitioning to the next allowable state. The transition states differed by treatment and the Markov termination condition was 36 months. Monthly transition probability estimates for state transitions, assuming constant rates, were calculated from rates obtained from RTOG 97-14 by the following equation; Monthly rate ϭ ͓Ϫln (1 Ϫ P)/n͔, where P is the probability of the occurrence of interest and n is the number of months the rate is measured. 7, 10 The monthly probability of the event is calculated using the following formula: Monthly probability ϭ 1 Ϫ exp(Ϫmonthly rate). Tree-Age Pro 2006, a healthcare decision analysis software (TreeAge Software, Inc. Williamstown, MA) was used to analyze the Markov Model. Sensitivity analyses were performed on the cost, transition probabilities, and utility values.
The occurrence of pain and the need for retreatment were assumed to be at the original site of treatment. Only the results of palliative treatment were included in the generation of the model.
Single and Multiple Fraction External Beam Radiation Therapy

Model
The models for single and multiple fraction radiation were the same except for the initial cost of the treatment and are depicted in 
Radiotherapy Cost
Costs were estimated based on usual and reasonable consumptions of resources for treatment of bone metastases. Global fees were used to account for both the technical aspect of treatment, such as the radiation treatment, and the professional or physician work aspect of treatment. A simple level of complexity was assumed for treatment planning, simulation, and treatment. No treatment devices were used. Table 1 outlines the current procedural terminology (CPT) codes that were used to derive the unit costs and were then matched to the Resource Value Units (RVUs). The RVUs were multiplied by the frequency of use, totaled, and multiplied by the 2008 national Medicare conversion factor of $38.087/RVU to arrive at a total cost in dollars. Visits to the doctor and other health care professionals were assumed to be equal across all treatment arms and were not included in the incremental analysis. The modeled costs were sampled using a range of costs listed in Table 2 . Costs were calculated from a payer's perspective, using Medicare as the model. The costs would have been different had a different perspective been adopted for the trial. Time away from home, travel costs, and lost productivity costs would have added additional costs to treatment had a patient perspective been used. Treatment cost, however, in this model may have been nonexistent whether the patient had insurance, which covered the treatment as only patient out-of-pocket expenses are covered in this model. RVU utilization was available for the initial treatment from patients treated at a minority of institutions that volunteered to collect these data. The cost of care was calculated by totaling the RVUs for the primary treatment and multiplying by the above conversion factor. RVU data were collected from 34 patients, 17 from each arm. Five patients in the multiple fraction arm were excluded because they had missing data, treatment management codes, etc, leaving 12 eligible and analyzable patients. One patient received only 1 fraction and was excluded as well. Six patients in the single fraction arm had missing data or received either 10 or 5 radiotherapy fractions and were excluded from the analysis, leaving 11 eligible and analyzable patients.
The mean cost of treatment for patients receiving a single fraction for actual trial participants was $1381 (range: 682-4271; SD: $1001). The mean cost of treatment for participants receiving multiple treatments was $3493 (range: 1316 -4657; SD: $1065).
The incremental cost-effectiveness ratio was calculated by comparing 8 Gy in 1 fraction as the standard treatment to 30 Gy in 10 fractions as the experimental treatment. 
Utilities
Utilities for each transition state were obtained from utilities collected from patients randomized on 97-14 and from van den Hout et al. 8 Utilities were collected with the Health Utilities Index III and were 0.43 before the initiation of the trial and 0.56 and 0.51 3 months after completing radiation for patients receiving 30 and 8 Gy, respectively. The utility for the retreatment state was assumed to be less than the initial utility of treatment (0.5) and that for patients receiving pain medications after failing retreatment was estimated at 0.2. A sensitivity analysis was used to test the utility assumptions.
Transition Probabilities
Overall survival at 3 years obtained from the trial was 5% and 17% for male and female patients receiving 8 Gy, respectively, and 10% and 23% for male and female patients receiving 30 Gy, respectively. The decision for retreatment was determined by the physician. Retreatment rates were 9% for the multiple fraction group and 18% for the single fraction group despite equal rates of analgesic use, totaling 68% and 67%, respectively, 3 months after completion of radiation therapy. 7
RESULTS
The expected mean cost for patients receiving 8 Gy was $996.77, with a quality-adjusted survival of 7.26 months. The expected mean cost for patients receiving 30 Gy was $2315.82, with a quality-adjusted survival of 9.53 months. The incremental cost-effectiveness ratio (ICER) was $6972.95/QALY. Sensitivity analysis was performed, testing the impact of the treatment assumptions, both cost and effect, on the overall outcome. Only posttreatment utility had an effect on which treatment was preferred. The 30 Gy in 10 fractions was favored over single fraction treatment as long as the utility for the posttreatment state was Ͼ0.43. That is, the longer treatment course is associated with a higher quality-adjusted life expectancy as long as the posttreatment quality of life is improved over the pretreatment quality of life (the pretrial utility is 0.43). The 8 Gy in 1 fraction arm would be favored if the utility for the posttreatment state was Ͼ0.67. In other words, the posttreatment utility after single fraction treatment would need to be higher than that after multiple fraction treatment for it to become the preferred strategy. The cost-effective acceptability curve is depicted in Figure 3 . The probability of being cost-effective at $4166/qualityadjusted life month is 100%. The normally accepted standard of cost-effectiveness is $50,000/QALY that is equivalent to $4166/ quality-adjusted life month. There was no difference in the outcome when another sensitivity analysis was performed using cost as calculated, using the Hospital Outpatient Prospective Payment System Ambulatory Payment Classification system.
Another way of reporting the results would be the cost in dollars per retreatment avoided. Ten patients receiving 30 Gy in 10 fractions had retreatment in comparison with 21 patients receiving 8 Gy in 1 fraction. The results in an incremental cost ratio of $131/retreatment avoided. Health policy decision makers, however, cannot use this ratio because it cannot be compared with other related health care interventions like breast cancer screening or diabetes care.
The expected mean cost for patients was $1009 and $2322 for patients treated with 8 and 30 Gy, respectively, when actual cost data was used with the same QALY for each treatment arm. This resulted in an ICER of $6956/QALY. 
DISCUSSION
The results of this economic analysis found that 30 Gy in 10 fractions was cost-effective in comparison with a single fraction because it prevented the need for additional retreatment. There was, however, a very small difference in quality of life, an approximate 2-month increase in quality-adjusted survival, with an approximate doubling of cost. The increase in marginal expected cost, however, was also very small at $1319. The small difference in the cost between single and multiple radiation fractionation schedules was also reported by van den Hout. 8 They reported only a small difference in cost of $873 favoring the single fraction arm. The difference was larger, $1753, when viewed from a societal viewpoint. The method they used in calculating the radiotherapy cost, however, differed from our method.
Cost-benefit analysis, cost-effectiveness analysis, cost-utility analysis, and cost-minimization analysis are the 4 different types of economic analyses. RTOG 97-14 was designed and powered as an equivalency trial with the primary end point being 1 fraction, which was same as 10 in relieving pain. With the primary end point being equivalence and with the end result as no difference in pain control, a cost-minimization analysis would be the economic analysis of choice. In cost-minimization analysis, the treatment with the least cost would be the preferred treatment. But, was there a difference between the 2 arms? The clinical result of 97-14 found no difference in pain control comparing 8 Gy in 1 fraction to 30 Gy in 10 fractions. Alternatively, the retreatment rate was significantly higher in the single fraction arm, resulting in the ICER being very small, well below the usual threshold of $50,000/LY or QALY as commonly quoted and the probability of cost-effectiveness was 100%. Johnston et al have recommended calculating cost-effectiveness ratios based on final end points even in situations were nonsignificant differences exists to avoid publication bias with estimation of the uncertainty in the ICER. 11 In this situation, the ICER reveals a favorable determination of cost-effectiveness even though the clinical trial result is 1 of 8 Gy being the preferred treatment. This analysis also found that the $/retreatment avoided was also low but unfortunately this value cannot be compared with any other metric of cost-effectiveness as it is specific for this intervention and could not be readily compared with other health care interventions.
Sensitivity analysis found that only if the utility of patients in the posttreatment state, receiving a single fraction of radiation was greater than 0.67 would multiple fraction treatment not be considered "cost-effective." It is very hard to imagine a clinical situation were this would be possible. Unfortunately, utilities of patients in this trial were not collected past the 3 month period so we cannot look to patients in this trial to determine whether this would be a clinically realistic expectation. van den Hout reported that the utilities of patients treated with either fraction of radiation did not increase over 0.6 in the posttreatment period in the Dutch Bone Metastasis Study, although they used a different method to determine utility. 8 A number of clinical trials have been performed comparing a single fraction to various multiple fractions in the treatment of patients with metastatic bone disease. All have found a single fraction equivalent to the many multiple fraction schedules used in relieving pain. The retreatment rates have been uniformly higher in the single fraction arm but the overall relief of pain has been equivalent regardless of the fractionation schedule. The decision for retreatment was determine by the physician in the RTOG, the Dutch Bone Metastases Trial, and other clinical trials evaluating a single fraction of palliative radiation. Higher rates of retreatment in single fraction arms of these studies have often been related to physician concerns for normal tissue tolerance with retreatment after multiple fraction palliative radiation. This may also be the case in the RTOG trial because narcotic use at 3 month follow-up was equivalent for single and multiple fraction arms.
It could be argued then that a single fraction should be the standard of care given the lower cost, both initial and overall. We have found that the use of multiple fractions, however, when required, is a cost-effective alternative to single fraction treatment. We have previously reported that unpartnered men receiving 8 Gy in 1 fraction had the same retreatment rate in comparison with unpartnered men receiving 30 Gy in 10 fractions. 7 The retreatment rate for all of the other gender/partner subgroups, partnered male and both female groups, receiving 8 Gy in 1 fraction was higher in comparison with 30 Gy in 10 fractions. It may be hypothesized that unpartnered males may not have the same social support for additional treatment even though they may be in pain. Multiple radiation fractions would be considered cost-effective in this patient subgroup if it were felt that they would not return for additional treatment if only given 1 treatment. The opportunity cost in time and lost productivity of patients and family for multiple fractions of radiation, however, is often difficult to assess. This is particularly important because partnered men and women had higher rates of retreatment.
The Dutch Bone Metastasis Study Group performed an economic analysis on a subgroup of patients who completed a cost questionnaire. Eighteen percent of patients in the single fraction group required retreatment in comparison with 5% in the multiple fraction group. A similar $/retreatment avoidance analysis results in $87/retreatment avoided if only medical costs are included and $175/retreatment avoided if societal costs are included. These numbers compare favorably to our analysis.
This study points to the difficulties adding an economic end point to a clinical trial. Outcome interpretation will become more difficult as treatments become more expensive with potentially small incremental gains in the primary endpoints. An example of this is the National Cancer Institute of Canada Clinical Trials Group comparison of erlotinib plus gemcitabine to gemcitabine alone in patients with locally advanced unresectable or metastatic pancreatic cancer. Overall survival based on an intention-to-treat analysis was significantly prolonged with the combination therapy arm, although the median survival was 6.24 months for the combination treatment in comparison with 5.91 months for the gemcitabine only arm, a difference of only 0.33 months. 12 The relatively small increase in survival comes at a high incremental cost. In the current study, there was no difference in the primary end point of pain relief with patients receiving a single fraction having a statistically higher retreatment rate. They still, however, had a lower expected mean cost, even including the retreatment and increased pain medicine usage. Despite this, the economic analysis found the ICER to be in the range of cost-effectiveness and the $/retreatment avoided was also very low.
Despite different economic methods used to analyze the respective clinical trials, this study confirms the results of the Dutch Bone Metastasis Study Group that single fraction radiation treatment is the most cost-effective in the treatment of bone metastasis. This study points to the difficulty that may be encountered in the future when economic analyses are incorporated or performed after the completion of clinical trials.
